Regenxbio (RGNX) Net Income towards Common Stockholders (2014 - 2025)

Regenxbio's Net Income towards Common Stockholders history runs 12 years deep, the most recent figure standing at $89.8 million for Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders rose 234.83% year-over-year to $89.8 million in Q4 2025; TTM through Dec 2025 was -$43.0 million, a 83.11% increase from a year earlier, with the FY2025 full-year figure at -$535.6 million, down 132.24% from the prior year.
• Net Income towards Common Stockholders advanced to $89.8 million in Q4 2025 per RGNX's latest filing, from -$65.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $294.0 million in Q4 2021 and bottomed at -$76.7 million in Q1 2022.
• The 5-year median for Net Income towards Common Stockholders is -$62.4 million (2023), against an average of -$18.7 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 735.85% in 2021; the steepest drop was 764.37% in 2021.
• Year by year, Net Income towards Common Stockholders stood at $294.0 million in 2021, then fell by 5.04% to $279.2 million in 2022, then plunged by 122.55% to -$63.0 million in 2023, then decreased by 5.8% to -$66.6 million in 2024, then surged by 234.83% to $89.8 million in 2025.
• Per Business Quant, the three latest RGNX Net Income towards Common Stockholders figures stand at $89.8 million (Q4 2025), -$65.5 million (Q3 2025), and -$70.9 million (Q2 2025).